Fоr eаch quоte, identify the аuthоr аnd title of the work. Give a 2-3 sentence discussion of its meaning within the selection. I’ve heard it in the chillest land - And on the strangest Sea - Yet - never - in Extremity, It asked a crumb - of me.
DRUG THERAPY OF ARRHYTHMIAS Clаss 0 — HCN Chаnnel Blоcker: Ivаbradine Mechanism оf Actiоn Blocks HCN (“funny”) channels in SA node→ ↓ Na⁺ If current→ ↓ slope of phase 4 depolarization→ ↓ HR & ↓ SA node automaticity Pharmacokinetics Oral Metabolized by CYP3A4 → drug interactions Excreted in feces & urine Uses Chronic HF (HR ≥ 70 bpm) Stable angina (HR ≥ 70 bpm) Sinus tachycardia Adverse Effects: Bradycardia Class I — Na⁺ Channel Blockers Class IA: Quinidine, Procainamide, Disopyramide Mechanism Moderate Na⁺ blockade→ ↓ depolarization rate→ ↑ AP duration & ↑ ERP→ Prolong QT Effects ↓ Automaticity ↓ Conduction ↑ Refractory period → ↓ reentry Uses SVT (AF, A-fib) VT/V-fib WPW (procainamide) Adverse Effects ⚠️ Torsades de pointes (QT prolongation) Disopyramide → anticholinergic (CI in myasthenia gravis) Quinidine → cinchonism, hemolysis (G6PD) Procainamide → lupus, bone marrow suppression Negative inotropy → CI in HF Class IB: Lidocaine, Mexiletine Mechanism: Weak Na⁺ blockade → ↓ AP duration Effects ↓ Automaticity ↓ Conduction & ↓ ERP Uses Ventricular arrhythmias (post-MI) Digitalis-induced arrhythmia Adverse Effects CNS toxicity (tremor, seizures) Lidocaine → neurotoxicity (high dose) Mexiletine → hepatotoxicity Negative inotropy Class IC: Flecainide, Propafenone Mechanism: Strong Na⁺ blockade → markedly ↓ depolarization → no change in AP duration Effects ↓ Automaticity ↓ Conduction → ↓ reentry ↑ QT interval Uses SVT (AF, A-fib) Resistant VT WPW Adverse Effects ⚠️ High pro-arrhythmic risk (boxed warning) Flecainide → ventricular arrhythmias Negative inotropy → CI in HF Propafenone → bronchospasm (β-blocking effect) Class II — Autonomic Modulators Class IIa — β-Blockers: Metoprolol, Atenolol, Propranolol, Esmolol, Carvedilol Mechanism: Block β1 → ↓ cAMP → ↓ phase 4 slope Effects ↓ HR (↓ SA node) ↓ AV conduction ↓ QT Uses SVT (especially stress-induced) Premature beats Atrial & ventricular arrhythmias Long QT syndrome Class IIb — β-Agonist: Isoproterenol Mechanism β1 → ↑ HR, conduction β2 → vasodilation Uses Bradycardia AV block (temporary) Torsades (bradycardia-dependent) Adverse Effects Tachyarrhythmias Hypotension Class IIc — M2 Antagonist: Atropine Mechanism: Blocks M2 receptors → ↑ SA automaticity → ↑ AV conduction Uses Bradycardia AV block Adverse Effects Anticholinergic: Dry mouth Blurred vision Urinary retention Tachycardia Class IId — M2 Activator: Digoxin Mechanism ↑ Vagal tone → ↓ HR & AV conduction Inhibits Na⁺/K⁺ ATPase → ↑ Ca²⁺ → ↑ contractility Uses AF (rate control when others not suitable) HFrEF (limited use now) Key Contraindications Hypokalemia Hypercalcemia AV block, bradycardia WPW with AF Adverse Effects Narrow therapeutic index GI, visual disturbances ⚠️ Arrhythmias Class IIe — Adenosine A1 Agonist: Adenosine Mechanism: ↑ K⁺ efflux, ↓ Ca²⁺ influx → hyperpolarization Effects ↓ SA node activity ↓ AV conduction Uses PSVT (first-line emergency) Adverse Effects Flushing, chest discomfort (~1 min) Bronchospasm (CI in asthma) Interactions ↓ effect: caffeine, theophylline Question: A 67-year-old man with chronic heart failure (ejection fraction 35%) presents for follow-up. He reports persistent elevated heart rate (~78–85 bpm) despite being on optimal guideline-directed medical therapy. Blood pressure is 118/72 mmHg. The provider considers adding a medication that selectively reduces SA node firing without affecting myocardial contractility. Which of the following is the most appropriate drug for this patient?
DRUG THERAPY OF ARRHYTHMIAS Clаss III — K⁺ Chаnnel Blоckers Clаss IIIa — Nоn-selective K⁺ Blоckers: Dofetilide, Ibutilide, Sotalol, Dronedarone Mechanism: Block K⁺ efflux → ↑ AP duration & ↑ ERP → Prolong QT Uses: AF, VT, VF, WPW Adverse Effects ⚠️ Torsades de pointes Dronedarone: CI in HF ↑ mortality in permanent AF Amiodarone (Special) “Antiarrhythmic shotgun” Class I, II, III, IV actions Pharmacokinetics Very long half-life (25–60 days) CYP3A4 interactions Uses Life-threatening arrhythmias only Major Adverse Effects (HIGH-YIELD) Pulmonary fibrosis Hepatotoxicity Hypo-/hyperthyroidism Corneal deposits Blue-gray skin discoloration Neurotoxicity Class IV — Ca²⁺ Channel Blockers: Verapamil, Diltiazem Mechanism: Block L-type Ca²⁺ channels Effects ↓ SA node automaticity ↓ AV conduction Uses SVT AF Miscellaneous: Magnesium Sulfate (MgSO₄) Mechanism: ↓ Ca²⁺ influx/release Uses Torsades de pointes (first-line) VT/VF (esp. hypomagnesemia) Adverse Effects Hypotension Respiratory depression ↓ reflexes Question: A 72-year-old woman is brought to the emergency department after a syncopal episode. ECG shows polymorphic ventricular tachycardia consistent with torsades de pointes. She has a prolonged QT interval on baseline ECG. Which of the following is the first-line treatment?